62,120 Shares in ADMA Biologics, Inc. (NASDAQ:ADMA) Bought by Intech Investment Management LLC

Intech Investment Management LLC purchased a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA) during the 3rd quarter, Holdings Channel.com reports. The fund purchased 62,120 shares of the biotechnology company’s stock, valued at approximately $1,242,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of ADMA. Bank of Montreal Can bought a new stake in ADMA Biologics in the second quarter valued at about $17,886,000. D. E. Shaw & Co. Inc. grew its stake in shares of ADMA Biologics by 26.8% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company’s stock valued at $76,298,000 after purchasing an additional 1,442,799 shares during the period. Principal Financial Group Inc. grew its stake in shares of ADMA Biologics by 785.7% in the 3rd quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company’s stock valued at $23,872,000 after purchasing an additional 1,059,394 shares during the period. First Turn Management LLC acquired a new position in shares of ADMA Biologics in the 3rd quarter worth approximately $13,293,000. Finally, Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of ADMA Biologics during the 2nd quarter worth approximately $6,468,000. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Trading Up 1.6 %

Shares of NASDAQ ADMA opened at $21.82 on Wednesday. ADMA Biologics, Inc. has a 1-year low of $3.60 and a 1-year high of $23.64. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The company has a 50-day moving average of $18.92 and a two-hundred day moving average of $15.05. The company has a market cap of $5.16 billion, a PE ratio of 77.93 and a beta of 0.64.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.02. The firm had revenue of $119.84 million for the quarter, compared to the consensus estimate of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same quarter in the prior year, the business earned $0.01 EPS. As a group, equities analysts expect that ADMA Biologics, Inc. will post 0.52 earnings per share for the current fiscal year.

Insider Activity at ADMA Biologics

In other news, CFO Brad L. Tade sold 15,000 shares of ADMA Biologics stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the completion of the sale, the chief financial officer now owns 199,433 shares in the company, valued at $4,218,007.95. The trade was a 7.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Jerrold B. Grossman sold 136,861 shares of the business’s stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $17.27, for a total transaction of $2,363,589.47. Following the sale, the director now directly owns 467,305 shares of the company’s stock, valued at approximately $8,070,357.35. This trade represents a 22.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 185,011 shares of company stock worth $3,255,204 over the last 90 days. Insiders own 3.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ADMA. HC Wainwright increased their price objective on ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Cantor Fitzgerald reissued an “overweight” rating and set a $20.00 price target on shares of ADMA Biologics in a report on Friday, September 20th. Finally, Raymond James upped their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research note on Friday, November 8th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.